Cocrystal reports SVR12 rate of 67% for CC-31244 regimen

Cocrystal Pharma Inc. (NASDAQ:COCP) reported preliminary data from an open-label, U.S. Phase IIa trial

Read the full 144 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE